Hedge Fund - VHCP Management

Biotech stocks pop and drop on the smallest whims and whispers, which makes the biotechnology sector one of the most rewarding and volatile sectors out there. Retail investors interested in high-potential...

Anders Hove and Bong Koh's VHCP Management disclosed a large increase in its Ocera Therapeutics (OCRX) stake. According to the latest 13F filings, Venrock had 700K shares of OCRX at the end of December...

At Insider Monkey, we look at the weighted average returns of the long positions a fund indicates in its 13F filings, in companies with a market cap greater than $1 billion, to estimate the returns of...

Biotech is a hot segment right now and even though it has many opportunities, it is also associated with a lot of risks. Out of hundreds of companies, it can be difficult to pick the real winners, but...

With losses in the high single-digits and volatility hitting the roof, the third quarter of 2015 turned out to be a troublesome period for the equity markets. While a lot of asset management firms suffered...

Andres Hove and Bong Koh’s VHCP Management revealed its top 3 biotech picks heading into 2015, in a 13F Form filed with the U.S. Securities and Exchange Commission last month. While Juno Therapeutics...